BenzingaOctober 27, 2026 at 4:47 AM NY13 Hours Ago
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146
Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
